Literature DB >> 7825966

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.

R Gomeni1, G Pineau, F Mentré.   

Abstract

The adjustment of individual dosage regimen is an adaptive control process based upon an individual response to a pharmacokinetic model. To attain this objective, it is very helpful to know the characteristics of the population to which the subject belongs, in terms of mean parameters and interindividual variability. Usually the available information consists of incomplete and sparse data. For this reason it is essential to employ a computational methodology based on non-linear mixed-effect procedures in order to obtain a population parameter estimate. A Bayesian methodology can then be applied from the population parameters to the specific data for the individual requiring a dosage adjustment (such data includes drug concentration(s) of the active drug, demographic data, etc). The result of the Bayesian calculation supplies the required individual pharmacokinetic parameters. An optimal dosage regimen can be defined on the basis of therapeutical criteria (concentration ranges) as well as practical constraints such as: the size of available unitary drug dosages, feasible drug intake times, penalties associated with expected concentrations falling outside the therapeutic concentration ranges. In this paper we present the methodology and results obtained using the P-Pharm software tool. P-Pharm implements a non-linear mixed-effect population parameter estimation algorithm based on the EM algorithm. This method allows the inclusion of explicit variables into the calculations, it implements an individual Bayesian parameter estimation procedure and also an algorithm for the conditional assessment of the optimal dosage regimen given a list of practical constraints.

Mesh:

Substances:

Year:  1994        PMID: 7825966

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation.

Authors:  Roberto Gomeni; Carla Dangeli; Alan Bye
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 2.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

3.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Authors:  Michaël Philippe; Michael Neely; Yves Bertrand; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

6.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

7.  Population pharmacokinetics and pharmacodynamics of oral etoposide.

Authors:  G Toffoli; G Corona; R Sorio; I Robieux; B Basso; A M Colussi; M Boiocchi
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

8.  Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.

Authors:  N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  Caffeine in apnoeic Asian neonates: a sparse data analysis.

Authors:  How Sung Lee; Yok Moi Khoo; Yazmin Chirino-Barcelo; Kim Leong Tan; Dorothy Ong
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

10.  Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.

Authors:  Kellie A Slaviero; Stephen J Clarke; Andrew J McLachlan; Elaine Y L Blair; Laurent P Rivory
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.